ARISE

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy

Topic / Pathology

  • Progressive Supranuclear Palsy (PSP)

Objectives

To have more informations, click on the link below: 

https://clinicaltrials.gov/ct2/show/NCT02985879?cond=PSP&cntry=FR&city=Toulouse

Sponsor

Abbvie

Scientific publication(s)

  • Höglinger GU et al; Arise Investigators.Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021 Mar;20(3):182-192. 

    https://pubmed.ncbi.nlm.nih.gov/33609476/

Status

Published results

Participating centers

Share

Updated on 15 February 2023